The antiulcer and antisecretory activity of WHR‐1370A 1‐n‐butoxy‐3‐(2,6 dimethylphenylcarbamoyl) guanidine hydrochloride

This is the authors' abstract. We don't add key points for this paper.

WHR‐1370A in the rat reduces volume (ED50 = 1.3 mg/kg p.o.) acidity (1.8 p.o.), and pepsin (2.8 p.o.) in the 4‐hr pylorus ligation model, delays gastric emptying (0.75 p.o.), and protects against the development of stress (18‐hr restraint)‐, indomethanic‐, aspirin‐, reserpine‐, and cysteamine‐induced ulcers (ED50s: 10.0 s.c., .65 p.o., 0.59 p.o., 3.0 p.o., and 8.0 s.c., respectively); also WHR‐1370A can completely suppress the cysteamine‐induced rise in serum gastrin. In the pylorus‐ligated rat, the activity of WHR‐1370A is not appreciably altered by methysergide, pimozide, propranolol, corynanthine, or phentolamine but is significantly and competitively antagonized by yohimbine. The pharmacological basis of WHR‐1370A probably can be attributed to an alpha‐2‐mediated inhibition of acetylcholine release at vagal nerve endings.